Bruce has Ph.D. in microbiology with over 25 years of both academic and industrial experience in life sciences research and development and commercialization of biotechnologies. He has managed the development and commercialization of environmental and microbial biotechnologies. Bruce pioneered research on the roles of iron in the pathogenesis of bacterial disease with more than 100 publications and 15 patents.
James Drage is the Managing Partner of Atlantic Venture Capital (AVC) Partners. AVC seeks to make a big investment of time and effort in order to be intimately involved at the formative stages of a company. After attending Dalhousie University in Halifax, NS for public administration and political science James began his working career in 1991 as a franchise and business broker. In 1995 he founded Business Opportunities and Investments and moved into mid- market M&A. While attending Royal Roads University James started Ebooks Press which was sold during the dot com boom. After working in New York in the M&A market, he returned to his roots in Nova Scotia full time in 2005 to work on a number of personal investment projects, including AVC.
Craig is the Director of Institute for Healthcare Innovation at Midwestern University. He has over 20 years of experience in clinical practice, industry and academia. He has expertise in translational research, clinical trials, due diligence, technology licensing and business development. Craig has been involved in starting several biomedical companies, established US divisions for international clients, and provided consultation for contract research organizations, laboratories, and various biomedical companies. Craig received his B.S. (biology), M.S. (Veterinary Anatomy), and D.V.M. from the University of Missouri, and his M.B.A. from Arizona State University.
Michael J. Weickert
Michael J. Weickert, PhD has been developing drugs, devices and startup companies for over 27 years, many in the anti-infective space. He has co-founded and/or led startups as CEO of Pacylex Pharmaceuticals, illumiSonics, Sonescence, and SEA Medical Systems, CBO of Strategent Life Sciences, Corium, and Therashock, COO of Ohm Oncology, VP of development at SciDose and Auspex. At startups, he raised Seed through Series C capital and established partnerships worth more than $180 Million. He has extensive experience developing anti-infectives, as CEO of Sonescence, a Phase 2 stage drug delivery startup addressing skin and soft tissue infections including involving MRSA, as Senior Program Executive at Nektar where he set up an anti-infectives business unit and directed the flagship anti-infective product from inception through Phase 2, as CBO of Therashock developing a new theory and therapy for sepsis, and as an advisor or consultant for companies like Pulmatrix, Taris, and Lightline. Michael has prepared over 40 business plans including for an anti-viral company founded by a Nobel Prize winner, and has driven product development from pre-clinical through Phase III/NDA. He obtained Orphan Drug and Fast Track designations for anti-infective products in the US and EU. Prior to joining the pharmaceutical industry, he was at the National Cancer Institute at NIH. He received his Ph.D. in Genetics from the University of Wisconsin.